Atossa Genetics may have taken a beating in the market yesterday after investors ran for the hills with fears of share dilution running wild after the breast cancer detection device maker revealed it needed to boost its cash flow. News of a registered direct offering of common stock made its way through the Street yesterday, with the company putting up for sale around 5.3 million shares. Though shares continue to plummet 4% this morning, perhaps the healthcare company hopes the grand reveal of a new Scientific Advisor will distract from the negative sentiment circulating the Street. The expert cherry-picked to be added to Atossa's Scientific Advisory Board? Dr. Carl Novina.
Dr. Novina is one of the leading researchers in the field of RNAi therapeutics. He is an Associate Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School and an Associate Member of the Broad Institute of Harvard and MIT. He is currently the Principal Investigator of the Novina Lab at the Dana-Farber Cancer Institute. His laboratory has made several important discoveries into the biology of noncoding RNAs, their dysregulation in cancers, and their development as biomedical tools.
More healthcare insights from a five-star Wall Street analyst: Transenterix Deal to Sell SurgiBot Outside of China Seems Like a Win-Win, Says Sean Lavin
Dr. Novina received his M.D. from Columbia University, College of Physicians and Surgeons in 2000 and his Ph.D. from Tufts University, Sackler School of Graduate Biomedical Sciences in 1998. His graduate work has resulted in 10 publications examining transcriptional regulation of TATA-less promoters. In 2014 he received the coveted National Institutes of Health Pioneer Award, which funds bold and innovative research proposals to attack challenging biomedical problems. Dr. Novina has established many collaborations between industry partners and physicians to facilitate his goal of bringing biomedical innovations from bench to bedside.
"We are delighted to welcome Dr. Novina to our Scientific Advisory Board which is composed of world-class experts in Breast Cancer research,” said Dr. Steve Quay, President and CEO of Atossa Genetics. “Dr. Novina’s immunology expertise will be invaluable as we develop our proprietary microcatheters for delivery of CAR-T cell therapies for the treatment of the deadlier forms of breast cancer.”
Atossa Genetics Inc., is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions.
More recent articles about ATOS:
- Atossa Genetics Inc Could Have an Asset That Kills Breast Cancer Cells Faster and Improves Clinical Outcomes; Jason Kolbert Weighs In
- Biotech Movers: Atossa Genetics Inc Raises on Back of Positive Early Clinical Data in Breast Cancer
- Atossa Genetics Inc: Could Accelerated Timelines to Approvals Lie Ahead? Jason Kolbert Weighs In
- The Report That Sent Atossa Genetics Inc Shares Skyrocketing